Guselkumab versus golimumab for active psoriatic arthritis
Treatments studied
Part of Bones, joints & muscles, Skin clinical trials.
This Phase 3 study compares two biologic medicines—guselkumab and golimumab—to see which works better for people with active psoriatic arthritis. It is designed for people whose psoriatic arthritis did not respond well to a prior “TNF-blocking” medicine (or lost response).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have psoriatic arthritis that meets specific diagnostic criteria (CASPAR).
- You have active psoriatic arthritis right now, meaning at least one swollen joint.
- Your symptoms score (cDAPSA) is high enough—typically 10 or more, with special rules if you have psoriasis versus not.
- You have tried a TNF blocker before (or you tried one in the past and it stopped working), and you plan to switch to a new biologic for this study.
- If you take methotrexate or similar pills/medicines, the dose must stay stable for 4 weeks before and during the study; same idea for low-dose steroids or certain psoriasis treatments.
- You cannot be pregnant or trying to become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether the drug guselkumab can help people who have both psoriatic arthritis and non-alcoholic fatty liver disease (NAFLD). If you are starting guselkumab for your psoriatic arthritis and have a fatty liver, you may be able to join.
This trial compares two drugs, apremilast and adalimumab, to see which is more effective for people with psoriatic arthritis who have not responded well to methotrexate. It focuses on joint pain, swelling, and skin symptoms.
This trial tests a new oral medicine (HS-10374) for people with active psoriatic arthritis who have not responded well to standard treatments. It compares the drug to a placebo to see if it reduces joint pain, swelling, and skin symptoms.
This study tests targeted medications for people with active psoriatic arthritis (PsA) who have already tried 1 or 2 other advanced treatments without success or couldn't tolerate them. The goal is to see if these newer options can better control joint pain and skin symptoms.
This study compares two “treat-to-target” strategies for psoriatic arthritis. One strategy uses imaging to guide treatment changes, and the other uses standard clinic assessments, to see which approach controls symptoms more effectively.
This trial studies how guselkumab works for people with long-lasting, more severe psoriasis and signs that may affect joints. It may help by improving psoriasis symptoms and possibly reducing related inflammation, while researchers track safety and outcomes.
Hear when a new Psoriatic Arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.